Document Detail


Inhibitors of propagation of coagulation: factors V and X.
MedLine Citation:
PMID:  21545479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular diseases are still the most important cause of morbidity and mortality in western countries and antithrombotic treatment is nowadays widely used. Drugs able to reduce coagulation activation are the treatment of choice for a number of arterial and/or venous thromboembolic conditions. Some of the drugs currently used for this purpose, such as heparins (UFH or LMWH) and VKA, have limitations consisting of a narrow therapeutic window and an unpredictable response with the need of laboratory monitoring in order to assess their efficacy and safety. These drawbacks have stimulated an active research aimed to develop new drugs able to act on single factors involved in the coagulation network, with predictable response. Intense experimental and clinical work on new drugs has focused on synthetic agents, which could preferably be administered orally and at fixed doses. The most advanced clinical development with new anticoagulants has been achieved for those inhibiting FXa and some of them, like fondaparinux, are already currently used in clinical practice. Other agents, such as rivaroxaban, apixaban, otamixaban and edoxaban are under development and have already been studied or are currently under investigation in large scale phase III clinical trials for prevention and treatment of venous thromboembolism, atrial fibrillation and acute coronary syndromes. Some of them have proved to be more effective than conventional therapy. Data on some agents inhibiting FVa are still preliminary and some of these drugs have so far been considered only in patients with disseminated intravascular coagulation secondary to sepsis.
Authors:
Vincenzo Toschi; Maddalena Lettino
Related Documents :
21377929 - Illicit drug knowledge and information-seeking behaviours among elite athletes.
21332249 - Reporting patterns indicative of adverse drug interactions: a systematic evaluation in ...
14562129 - Towards evidence-based drug treatment research on premature ejaculation: a critical eva...
8347899 - Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving ...
15805999 - Out-of-season recollection of drug use for seasonal ige-mediated rhinitis: useful but a...
15363569 - On-demand treatment of premature ejaculation with clomipramine and paroxetine: a random...
23035929 - Dmet-analyzer: automatic analysis of affymetrix dmet data.
21045169 - Rhabdomyolysis in a patient receiving high-dose simvastatin after the induction of ther...
2238129 - Differential effects of free and liposome encapsulated amikacin on the survival of myco...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  72     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-12     Completed Date:  2012-01-12     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  563-80     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
Affiliation:
Department of Hematology and Blood Transfusion, Thrombosis Center, San Carlo Borromeo Hospital, Milan, Italy. vincenzo.toschi1@alice.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / prevention & control
Anticoagulants / pharmacology
Blood Coagulation / drug effects
Blood Coagulation Factor Inhibitors / pharmacology*
Factor V / antagonists & inhibitors*
Factor X / antagonists & inhibitors*
Humans
Stroke / prevention & control
Venous Thromboembolism / prevention & control
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Blood Coagulation Factor Inhibitors; 9001-24-5/Factor V; 9001-29-0/Factor X
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasma Vaspin Concentrations Are Elevated in Metabolic Syndrome in Men and Are Correlated with Coron...
Next Document:  How to manage hypertension in pregnancy effectively.